Remolonas
Remolonas sells food that has lost its usual commercial outlet through personalised subscriptions and online orders.
UndisclosedAnnounced financing
ParticipantCC
Clave Capital
Activity from announced rounds
Activity in this selectionOct 27, 2026 · Jul 30, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $3.6M 1 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionConnecta Therapeutics
Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome.
€3.1MClinical development financing
Lead